Back to Forecasting
SMMT Forecast Markets
Summit Therapeutics, Inc.
7
Active Markets
57%
Avg Probability
All Markets
7 markets
Will the FDA approve ivonescimab (HARMONi BLA) by the November 14, 2026 PDUFA date?
32%
Likely No
82% agreement
Nov 30, 2026
IG: 1.00
Will HARMONi-3 squamous interim PFS analysis report statistically significant results by Q3 2026?
60%
Likely Yes
82% agreement
Sep 30, 2026
IG: 0.80
Will Summit report interim OS data from HARMONi-3 before the November 14 PDUFA date?
52%
Likely Yes
78% agreement
Nov 14, 2026
IG: 0.80
Will SMMT maintain a market capitalization above $10B through September 2026?
55%
Likely Yes
80% agreement
Oct 15, 2026
IG: 0.64
Will Summit Therapeutics maintain at least 4 quarters of cash runway through Q2 2026?
75%
Likely Yes
82% agreement
Aug 31, 2026
IG: 0.48
Will SMMT insiders remain net buyers (zero dispositions) through H1 2026?
75%
Likely Yes
84% agreement
Jul 15, 2026
IG: 0.48
Will Summit confirm FDA-validated US manufacturing capability for ivonescimab by PDUFA date?
48%
Likely No
78% agreement
Nov 30, 2026
IG: 0.48
Resolution Timeline
Jul 15, 2026
Will SMMT insiders remain net buyers (zero dispositions) through H1 2026?Prediction: 75%
Aug 31, 2026
Will Summit Therapeutics maintain at least 4 quarters of cash runway through Q2 2026?Prediction: 75%
Sep 30, 2026
Will HARMONi-3 squamous interim PFS analysis report statistically significant results by Q3 2026?Prediction: 60%
Oct 15, 2026
Will SMMT maintain a market capitalization above $10B through September 2026?Prediction: 55%
Nov 14, 2026
Will Summit report interim OS data from HARMONi-3 before the November 14 PDUFA date?Prediction: 52%
Nov 30, 2026
Will the FDA approve ivonescimab (HARMONi BLA) by the November 14, 2026 PDUFA date?Prediction: 32%
Nov 30, 2026
Will Summit confirm FDA-validated US manufacturing capability for ivonescimab by PDUFA date?Prediction: 48%